Solvonis Therapeutics plc
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-cl… Read more
Solvonis Therapeutics plc (SVNS) - Total Assets
Latest total assets as of June 2025: GBX9.54 Million GBX
Based on the latest financial reports, Solvonis Therapeutics plc (SVNS) holds total assets worth GBX9.54 Million GBX as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Solvonis Therapeutics plc - Total Assets Trend (2018–2024)
This chart illustrates how Solvonis Therapeutics plc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Solvonis Therapeutics plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Solvonis Therapeutics plc's total assets of GBX9.54 Million consist of 25.4% current assets and 74.6% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 23.6% |
| Accounts Receivable | GBX0.00 | 0.0% |
| Inventory | GBX0.00 | 0.0% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX0.00 | 0.0% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Solvonis Therapeutics plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Solvonis Therapeutics plc's current assets represent 25.4% of total assets in 2024, an increase from 12.9% in 2018.
- Cash Position: Cash and equivalents constituted 23.6% of total assets in 2024, up from 11.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 66.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Solvonis Therapeutics plc Competitors by Total Assets
Key competitors of Solvonis Therapeutics plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hanil Vacuum Co. Ltd
KQ:123840
|
Korea | ₩115.98 Billion |
|
Ivisionworks Co.,Ltd.
KQ:469750
|
Korea | ₩50.10 Billion |
|
Huayi Compressor Co Ltd
SHE:000404
|
China | CN¥15.16 Billion |
|
Shenyang Machine Tool Co Ltd
SHE:000410
|
China | CN¥9.63 Billion |
|
North Industries Group Red Arrow Co Ltd
SHE:000519
|
China | CN¥17.38 Billion |
|
Changchai Co Ltd
SHE:000570
|
China | CN¥5.30 Billion |
|
Jiangsu Youli Investment Holding Co Ltd
SHE:000584
|
China | CN¥3.49 Billion |
|
Baota Industry Co Ltd
SHE:000595
|
China | CN¥9.54 Billion |
Solvonis Therapeutics plc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Solvonis Therapeutics plc generates 0.24x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Solvonis Therapeutics plc is currently not profitable relative to its asset base.
Solvonis Therapeutics plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.13 | 0.15 | 0.04 |
| Quick Ratio | 1.13 | 0.15 | 0.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX204.00K | GBX -413.00K | GBX -853.00K |
Solvonis Therapeutics plc - Advanced Valuation Insights
This section examines the relationship between Solvonis Therapeutics plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 31.6% |
| Total Assets | GBX3.20 Million |
| Market Capitalization | $0.27 USD |
Valuation Analysis
Below Book Valuation: The market values Solvonis Therapeutics plc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Solvonis Therapeutics plc's assets grew by 31.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Solvonis Therapeutics plc (2018–2024)
The table below shows the annual total assets of Solvonis Therapeutics plc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX3.20 Million | +31.59% |
| 2023-12-31 | GBX2.43 Million | -50.72% |
| 2022-12-31 | GBX4.94 Million | +57.80% |
| 2021-12-31 | GBX3.13 Million | +13.20% |
| 2021-05-31 | GBX2.77 Million | +6.63% |
| 2020-05-31 | GBX2.59 Million | -6.12% |
| 2019-05-31 | GBX2.76 Million | -10.82% |
| 2018-05-31 | GBX3.10 Million | -- |